Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
DAMICO JENNIFER B. | SVP & Controller | Jun 07 | Sale | 53.96 | 4,218 | 227,603 | 10,846 | Jun 08 04:43 PM | DAMICO JENNIFER B. | SVP & Controller | May 16 | Sale | 50.50 | 4,000 | 202,000 | 15,064 | May 17 07:48 AM | SAHNI PAYAL | Executive Vice President | May 13 | Sale | 49.84 | 1,408 | 70,175 | 17,372 | May 16 09:23 PM | Carapezzi William R JR | Executive Vice President | May 12 | Sale | 50.00 | 32,908 | 1,645,400 | 38,146 | May 13 05:38 PM | LANKLER DOUGLAS M | Executive Vice President | May 12 | Sale | 49.41 | 38,273 | 1,891,069 | 78,803 | May 13 05:19 PM | Dolsten Mikael | President R&D | May 11 | Sale | 49.32 | 63,902 | 3,151,547 | 333,342 | May 12 04:34 PM | Dolsten Mikael | President R&D | Mar 03 | Option Exercise | 31.83 | 102,460 | 3,261,036 | 396,578 | Mar 04 04:13 PM | DAMELIO FRANK A | Executive Vice President | Feb 26 | Option Exercise | 25.60 | 127,160 | 3,255,296 | 649,918 | Mar 01 05:55 PM | SUSMAN SALLY | Executive Vice President | Feb 26 | Option Exercise | 25.60 | 63,580 | 1,627,648 | 172,880 | Mar 01 05:55 PM | DAMICO JENNIFER B. | SVP & Controller | Feb 26 | Option Exercise | 25.60 | 9,713 | 248,653 | 26,120 | Mar 01 04:02 PM | LANKLER DOUGLAS M | Executive Vice President | Feb 26 | Option Exercise | 25.60 | 77,709 | 1,989,350 | 174,507 | Mar 01 04:03 PM | McDermott Michael | Executive Vice President | Feb 26 | Option Exercise | 25.60 | 12,340 | 315,904 | 83,530 | Mar 01 04:03 PM | Carapezzi William R JR | Executive Vice President | Feb 26 | Option Exercise | 25.60 | 21,193 | 542,541 | 87,363 | Mar 01 04:03 PM | Carapezzi William R JR | Executive Vice President | Feb 23 | Option Exercise | 27.34 | 25,632 | 700,779 | 82,914 | Feb 25 05:06 PM | SAHNI PAYAL | Executive Vice President | Feb 23 | Option Exercise | 27.34 | 13,884 | 379,589 | 29,391 | Feb 25 06:27 PM | SUSMAN SALLY | Executive Vice President | Feb 23 | Option Exercise | 27.34 | 76,895 | 2,102,309 | 166,470 | Feb 25 06:29 PM | Hwang Angela | Group President | Feb 23 | Option Exercise | 27.34 | 21,359 | 583,955 | 21,359 | Feb 25 06:10 PM | LANKLER DOUGLAS M | Executive Vice President | Feb 23 | Option Exercise | 27.34 | 115,342 | 3,153,450 | 181,659 | Feb 25 06:20 PM | DAMELIO FRANK A | Executive Vice President | Feb 23 | Option Exercise | 27.34 | 153,789 | 4,204,591 | 636,977 | Feb 25 06:04 PM | JOHNSON RADY A | Executive Vice President | Feb 23 | Option Exercise | 27.34 | 35,457 | 969,394 | 91,301 | Feb 25 06:17 PM | DAMICO JENNIFER B. | SVP & Controller | Feb 23 | Option Exercise | 27.34 | 11,748 | 321,190 | 21,668 | Feb 25 05:46 PM | Dolsten Mikael | President R&D | Dec 17 | Option Exercise | 30.17 | 71,187 | 2,147,712 | 351,637 | Dec 21 06:31 PM | BOURLA ALBERT | Chairman & CEO | Dec 17 | Option Exercise | 26.73 | 123,055 | 3,289,547 | 246,444 | Dec 21 06:03 PM | JOHNSON RADY A | Executive Vice President | Dec 03 | Sale | 53.42 | 19,000 | 1,015,042 | 55,844 | Dec 06 05:18 PM | MACKENZIE ALEXANDER R | Executive Vice President | Dec 02 | Sale | 54.26 | 41,360 | 2,244,194 | 87,280 | Dec 06 05:18 PM | SUSMAN SALLY | Executive Vice President | Nov 26 | Sale | 54.52 | 44,308 | 2,415,578 | 89,575 | Nov 30 04:30 PM | LANKLER DOUGLAS M | Executive Vice President | Nov 26 | Sale | 54.37 | 40,000 | 2,174,786 | 66,317 | Nov 30 04:30 PM | Hwang Angela | Group President | Nov 12 | Sale | 49.60 | 26,170 | 1,298,002 | 1 | Nov 15 05:32 PM | Dolsten Mikael | President R&D | Nov 11 | Option Exercise | 25.13 | 199,548 | 5,014,926 | 339,506 | Nov 15 05:40 PM | Dolsten Mikael | President R&D | Nov 11 | Sale | 50.29 | 59,664 | 3,000,647 | 279,842 | Nov 15 05:40 PM | YOUNG JOHN D | Group President | Nov 11 | Sale | 50.06 | 150,000 | 7,508,732 | 312,704 | Nov 12 06:08 PM | DAMICO JENNIFER B. | SVP & Controller | Aug 13 | Sale | 48.30 | 1,661 | 80,226 | 9,769 | Aug 16 08:12 PM | DAMICO JENNIFER B. | SVP & Controller | Jul 30 | Sale | 42.86 | 2,500 | 107,150 | 11,430 | Aug 02 07:02 PM |
|